A single center evaluation of cost savings related to treatment-free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco-economy larger study Keywords: tyrosine kinase inhibitors; treatment-free remission; cost savings EN tyrosine kinase inhibitors treatment-free remission cost savings e97 e100 4 04/30/20 20200501 NES 200501 Several studies have now demonstrated that first and second generation tyrosine kinase inhibitors (TKI) can be safely discontinued in patients who have achieved a sustained deep molecular response (Mahon I et al i ., [4]; Ross I et al i ., [7]; Rousselot I et al i ., [8]; Imagawa I et al i ., [3]; Mori I et al i ., [5]; Rea I et al i ., [6]; Hochhaus I et al i ., [2]; Etienne I et al i ., [1]). However, even if these cost savings are different from country to country, as they probably would be, TKI could currently be safely discontinued and associated for some patients with prolonged TFR, generating major cost savings. [Extracted from the article]